Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 6:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1249–1272 of 2,904 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control Capsules Clear all
Completed Phase 3 Interventional Results available

Study of Cabozantinib (XL184) Versus Prednisone in Men With Metastatic Castration-resistant Prostate Cancer Previously Treated With Docetaxel and Abiraterone or MDV3100

NCT01605227
View directory record Official record
Conditions
Prostate Cancer, Castration Resistant Prostate Cancer, Pain, Prostatic Neoplasms
Interventions
cabozantinib, prednisone
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,028 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Phoenix, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2018 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Bexarotene Amyloid Treatment for Alzheimer's Disease

NCT01782742
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Bexarotene, Placebo
Drug
Lead sponsor
The Cleveland Clinic
Other
Eligibility
50 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Oct 31, 2026, 6:35 AM EDT
Terminated Phase 2 Interventional Results available

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

NCT02927366
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
QCC374, Placebo Matching
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of RHH646 for Knee Osteoarthritis

NCT05816395
View directory record Official record
Conditions
Osteoarthritis, Knee
Interventions
RHH646, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
35 Years to 75 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
4
States / cities
Lincoln, California • Winter Park, Florida • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 4 Interventional Results available

Topiramate Treatment of Alcohol Use Disorders in Veterans With Post Traumatic Stress Disorder (PTSD): A Pilot Controlled Trial of Augmentation Therapy

NCT01087736
View directory record Official record
Conditions
PTSD, Alcohol Abuse, Alcoholism
Interventions
Topiramate, Placebo administration
Drug · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 3, 2014 · Synced Oct 31, 2026, 6:35 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Oral Nutraceutical Supplement With Standardized Botanicals in Males With Self-Perceived Thinning Hair and Loss

NCT03709563
View directory record Official record
Conditions
Hair Loss, Hair Thinning
Interventions
Oral Nutraceutical Supplement, Placebo
Dietary Supplement
Lead sponsor
DeNova Research
Other
Eligibility
21 Years to 45 Years · Male only
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2023 · Synced Oct 31, 2026, 6:35 AM EDT
Not listed Phase 4 Interventional

Pilot Study of Lovaza (Omega 3 Fatty Acids) to Improve Cardiac Antioxidant/Anti-inflammatory Profile Before Cardiac Surgery

NCT01046604
View directory record Official record
Conditions
Mitral Valve Regurgitation, Left Atrium Dilatation and Hypertrophy, Mitochondrial Dysfunction in the Heart, Cardiomyocyte Apoptosis, Cardiac Inflammation
Interventions
Lovaza group
Drug
Lead sponsor
East Carolina University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 10, 2013 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 3 Interventional

A Trial of Centanafadine Efficacy and Safety in Children With Attention-deficit/ Hyperactivity Disorder (ADHD)

NCT05428033
View directory record Official record
Conditions
Attention Deficit/Hyperactivity Disorder
Interventions
centanafadine capsule, placebo capsule
Drug · Other
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
4 Years to 12 Years
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 31, 2026, 6:35 AM EDT
Terminated No phase listed Observational

A Study to Assess Patient-Reported Quality of Life and Effectiveness on Control of Bleeding in Adult Participants With Heavy Menstrual Bleeding Due to Uterine Fibroids Taking Oral Oriahnn Capsules

NCT05026502
View directory record Official record
Conditions
Heavy Menstrual Bleeding, Uterine Fibroids
Interventions
Not listed
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 51 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

NCT00509145
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Laquinimod, Placebo
Drug · Other
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
1,106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
23
States / cities
Phoenix, Arizona • Centennial, Colorado • Fort Collins, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Not applicable Interventional Results available

Efficacy and Safety of Vibrant Capsule vs. Placebo for the Treatment of Chronic Idiopathic Constipation

NCT03879239
View directory record Official record
Conditions
Chronic Idiopathic Constipation
Interventions
Vibrating capsule
Device
Lead sponsor
Vibrant Ltd.
Industry
Eligibility
22 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
8
States / cities
Foley, Alabama • Tucson, Arizona • Augusta, Georgia + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2024 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

OEA for Targeting Lipid Metabolism in GWI

NCT05252949
View directory record Official record
Conditions
Gulf War Illness
Interventions
Oleoylethanolamide (OEA), Placebo
Dietary Supplement
Lead sponsor
Roskamp Institute Inc.
Other
Eligibility
Up to 70 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
1
States / cities
Sarasota, Florida
Source: ClinicalTrials.gov public record
Updated Aug 8, 2025 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

RCT of Fomitopsis Officinalis and Trametes Versicolor to Treat COVID-19

NCT04667247
View directory record Official record
Conditions
COVID-19
Interventions
FoTv
Drug
Lead sponsor
Gordon Saxe
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
2
States / cities
Los Angeles, California • San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 3 Interventional Results available

Extension Study to Evaluate the Safety and Efficacy of PT003, PT001, and PT005 in Subjects With Moderate to Very Severe COPD, With Spiriva® Handihaler® (PINNACLE 3)

NCT01970878
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD)
Interventions
GFF MDI (PT 003), GP MDI (PT001), FF MDI (PT005), Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)
Drug
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
892 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
110
States / cities
Andalusia, Alabama • Anniston, Alabama • Athens, Alabama + 107 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2017 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

A Study of Repeat Dosing of OROS® Methylphenidate Hydrochloride (CONCERTA®) and Immediate Release Methylphenidate Hydrochloride in Healthy Adults

NCT00302458
View directory record Official record
Conditions
Healthy
Interventions
OROS-Methylphenidate, Immediate Release Methylphenidate, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate Safety, Tolerability, and Efficacy of GS-0976 in Adults With Nonalcoholic Steatohepatitis

NCT02856555
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Firsocostat, Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
36
States / cities
Coronado, California • Foster City, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 3 Interventional

A 52-Week Study of Ritlecitinib Oral Capsules in Adults and Adolescents With Nonsegmental Vitiligo (Active and Stable) Tranquillo

NCT05583526
View directory record Official record
Conditions
Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
Interventions
Ritlecitinib, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
607 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
46
States / cities
Birmingham, Alabama • Encinitas, California • Huntington Beach, California + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 3 Interventional Results available

A Study of Flexible-dose Brexpiprazole as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder, the Delphinus Trial

NCT01727726
View directory record Official record
Conditions
Depressive Disorder, Depression, Depressive Disorder, Major, Mood Disorders, Mental Disorders
Interventions
Brexpiprazole, Seroquel XR, Placebo
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
2,182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
44
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2018 · Synced Oct 31, 2026, 6:35 AM EDT
Not listed Phase 4 Interventional Results available

Effectiveness of Deep Brain Stimulation for Treating People With Treatment Resistant Obsessive-Compulsive Disorder

NCT00640133
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Active DBS, Sham DBS
Device
Lead sponsor
Butler Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2024
U.S. locations
9
States / cities
Redwood City, California • Washington D.C., District of Columbia • Gainesville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

NCT03606057
View directory record Official record
Conditions
Healthy
Interventions
JNJ-64565111, Moxifloxacin, JNJ-64565111-matching Placebo, Moxifloxacin-matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study

NCT04488601
View directory record Official record
Conditions
Aging
Interventions
Rapamycin, Placebo
Drug
Lead sponsor
AgelessRx
Industry
Eligibility
50 Years to 85 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-Time-in-Humans Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of SB756050

NCT00607906
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
SB-756050 immediate release capsule, SB-756050 modified release capsule, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 60 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 6, 2017 · Synced Oct 31, 2026, 6:35 AM EDT
Terminated Phase 2 Interventional

Oral Tonapofylline (BG9928) in Patients With Heart Failure and Renal Insufficiency

NCT00745316
View directory record Official record
Conditions
Renal Insufficiency, Heart Failure
Interventions
Tonapofylline, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
30
States / cities
Huntsville, Alabama • Mobile, Alabama • Scottsdale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 11, 2023 · Synced Oct 31, 2026, 6:35 AM EDT
Completed Phase 1 Interventional

Hematopoietic Stem Cell Transplant Survivors Study

NCT02652052
View directory record Official record
Conditions
Stem Cell Transplant
Interventions
Standard of Care - Observation Only, Group 2: Quercetin, Group 2: Dasatinib
Other · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 31, 2026, 6:35 AM EDT